Tom van Gils

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Christophe Cellier, Gerd Bouma, Tom van Gils et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 100 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +10

Prevalence and Characterization of Self-Reported Gluten Sensitivity in The Netherlands

Tom van Gils, Petula Nijeboer, Catharina IJssennagger et al. · Nutrients · 2016 · 96 citations · Full text

Agriculture, Food Science, Nutrition +13

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study

Morgane Cheminant, Julie Bruneau, Georgia Malamut et al. · Gut · 2018 · 60 citations · Full text

Life Sciences, Immunology, Pathology +17

CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes

Yvonne Kooy–Winkelaar, Dagmar Bouwer, George M. C. Janssen et al. · Proceedings of the National Academy of Sciences · 2017 · 57 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer

Yvette H. van Beurden, Tom van Gils, Nienke A. Van Gils et al. · Journal of Gastrointestinal and Liver Diseases · 2016 · 54 citations · Full text

Life Sciences, Immunology, Microbiology +17